Our informational symposium at #ASPN2024 starts at noon tomorrow and will emphasize the evidence behind Prospera™: ➡️ Learn about a robust clinical program that dates back to 2017 and includes multiple studies supporting therapy development, therapy validation, and a real-world study that validates the need for patient support beyond the implant. ➡️ Hear how proactive care is positively impacting patients, as demonstrated by real-world results from clinical practice. Don’t miss this opportunity to register: https://ow.ly/yf9M50Sv2Uu #BIOTRONIKNeuro #SpinalCordStimulation
BIOTRONIK Neuro’s Post
More Relevant Posts
-
Whether it's cystic fibrosis or ulcerative colitis, we understand the unique nuances of internal medicine trials. Recognizing the need for customized strategies across subspecialties, our team of therapeutically aligned experts take a tailored approach to navigating the complexities of your clinical trial – developing and implementing optimal clinical strategies, and maximizing patient impact. Learn more. https://bit.ly/3Xg3AbX #medicinetrials #clinicaltrials #patientimpact
-
-
Whether it's cystic fibrosis or ulcerative colitis, we understand the unique nuances of internal medicine trials. Recognizing the need for customized strategies across subspecialties, our team of therapeutically aligned experts take a tailored approach to navigating the complexities of your clinical trial – developing and implementing optimal clinical strategies, and maximizing patient impact. Learn more. https://bit.ly/4deee94 #InternalMedicine #clinicaltrials
-
-
Whether it's cystic fibrosis or ulcerative colitis, we understand the unique nuances of internal medicine trials. Recognizing the need for customized strategies across subspecialties, our team of therapeutically aligned experts take a tailored approach to navigating the complexities of your clinical trial – developing and implementing optimal clinical strategies, and maximizing patient impact. Learn more. https://bit.ly/40j8oAG #InternalMedicine #clinicaltrials
-
-
Whether it's cystic fibrosis or ulcerative colitis, we understand the unique nuances of internal medicine trials. Recognizing the need for customized strategies across subspecialties, our team of therapeutically aligned experts take a tailored approach to navigating the complexities of your clinical trial – developing and implementing optimal clinical strategies, and maximizing patient impact. Learn more. https://bit.ly/4i1MGay #InternalMedicine #clinicaltrials
-
-
In case you missed it, a recent article in Journal of Clinical Medicine (JCM) MDPI showed consistent performance for SeptiCyte® RAPID in diagnosing #sepsis across different patient subgroups as defined by combinations of demographic or clinical variables. Read the article here: https://bit.ly/3Y3MrTf
-
-
We are excited to share news about our GRACE clinical trial and look forward to providing more insights about this pivotal Phase 3 study of patients with #hypercortisolism soon. Read more in today’s press release: https://bit.ly/45gVLqh #CortisolModulation #ClinicalTrial
-
-
We demystify the systematic literature review (SLR) process in our December 5 webinar by providing an overview of the steps involved in conducting an SLR, when to conduct an SLR, and how SLRs contribute to evidence-based medicine and improve patient outcomes. Register herehttps://lnkd.in/eRuq5Up7
-
-
Business Development Manager - Immunexpress / SeptiCyte RAPID - 1st FDA cleared host-response, Gene Expression, for Sepsis, that aids clinicians to make time sensitive decisions to reduce mortality!
DM me to schedule a meeting to learn more about our solution and how it can help reduce mortality and improve your sepsis bundle compliance.
A recent study published in Journal of Clinical Medicine (JCM) demonstrated that SeptiCyte® RAPID consistently and accurately diagnosed #sepsis across various patient subgroups, defined by diverse demographic and clinical factors. Read the article here: https://bit.ly/3Y3MrTf
-
-
The James Lind Care trial attractiveness model offers a valuable framework for understanding and enhancing patient participation in clinical studies. By focusing on five key factors—Incentives, Benefit, Purpose, Ease, and Intervention—the model captures the essence of what motivates patients to engage in research. Together, these factors improve the patient recruitment and retention in the clinical trial. For more detailed information, visit the James Lind Care trial attractiveness model at https://lnkd.in/ddv97NRy. #JamesLindCare #TrialAttractiveness #ClinicalStudies
-
-
We had to ask! Our research uncovered several key factors that are driving the disconnect between HCPs and Patients! Now building multifaceted solutions is key to driving success. #ClinicalStudies #Insights #recuitment
People need treatment, #ClinicalStudies need people – where is the disconnect? AXON spoke with 100+ #InternalMedicine Specialists across the #US, and our #research showed that doctors are not well informed, with 59% stating that they are not always up to date on clinical studies and 42% saying that they do not have time to find out. AXON has examined the perceptions, assumptions, and barriers of the primary gatekeepers to #ClinicalTrial recruitment and retention. Download our report, which explores barriers to #ClinicalTrialRecruitment and the possible solutions for getting new treatments to patients. https://lnkd.in/ettfYaDp #Insights #POV #ThoughtLeadership #OwnedData #LifeAtAXON
